Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
177.28
+2.21 (1.26%)
At close: Sep 11, 2026, 4:00 PM EDT
173.79
-3.49 (-1.97%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Belite Bio Employees
Belite Bio had 41 employees as of December 31, 2025. The number of employees increased by 16 or 64.00% compared to the previous year.
Employees
41
Change (1Y)
16
Growth (1Y)
64.00%
Revenue / Employee
n/a
Profits / Employee
-$2,496,683
Market Cap
7.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 41 | 16 | 64.00% |
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
BLTE News
- 1 day ago - Belite Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 3 days ago - Belite Bio price target raised to $234 from $220 at Mizuho - TheFly
- 4 days ago - Belite Bio price target raised to $245 from $214 at H.C. Wainwright - TheFly
- 4 days ago - Belite Bio Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 days ago - Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1 - TheFly
- 4 days ago - Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 - GlobeNewsWire
- 8 days ago - Canaccord starts Belite Bio at Buy on additional post-IPO upside - TheFly
- 8 days ago - Belite Bio initiated with a Buy at Canaccord - TheFly